These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 33988338

  • 1. Long-term Efficacy and Safety of Everolimus Versus Mycophenolate in Kidney Transplant Recipients Receiving Tacrolimus.
    Nunes Ficher K, Dreige Y, Gessolo Lins PR, Nicolau Ferreira A, Toniato de Rezende Freschi J, Linhares K, Stopa Martins S, Custodio L, Cristelli M, Viana L, Wagner Santos D, de Marco R, Gerbase-DeLima M, Proença H, Aguiar W, Nakamura M, Rosso Felipe C, Medina Pestana J, Tedesco Silva H.
    Transplantation; 2022 Feb 01; 106(2):381-390. PubMed ID: 33988338
    [Abstract] [Full Text] [Related]

  • 2. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A, Felipe C, Cristelli M, Viana L, Basso G, Stopa S, Mansur J, Ivani M, Bessa A, Ruppel P, Aguiar W, Campos E, Gerbase-DeLima M, Proença H, Tedesco-Silva H, Medina-Pestana J.
    Am J Nephrol; 2017 Feb 01; 45(6):497-508. PubMed ID: 28511172
    [Abstract] [Full Text] [Related]

  • 3. Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.
    Miranda TA, Felipe CR, Santos RHN, Medina Pestana JO, Tedesco-Silva Junior H.
    Ther Drug Monit; 2020 Dec 01; 42(6):811-820. PubMed ID: 32657909
    [Abstract] [Full Text] [Related]

  • 4. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Witzke O, Hugo C, Kamar N, Merville P, Junge M, Thaiss F, Nashan B, Athena Study Group.
    Kidney Int; 2019 Jul 01; 96(1):231-244. PubMed ID: 31027892
    [Abstract] [Full Text] [Related]

  • 5. Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.
    Tedesco-Silva H, Felipe C, Ferreira A, Cristelli M, Oliveira N, Sandes-Freitas T, Aguiar W, Campos E, Gerbase-DeLima M, Franco M, Medina-Pestana J.
    Am J Transplant; 2015 Oct 01; 15(10):2655-64. PubMed ID: 25988935
    [Abstract] [Full Text] [Related]

  • 6. A Head-to-head Comparison of De Novo Sirolimus or Everolimus Plus Reduced-dose Tacrolimus in Kidney Transplant Recipients: A Prospective and Randomized Trial.
    Toniato de Rezende Freschi J, Cristelli MP, Viana LA, Ficher KN, Nakamura MR, Proença H, Dreige YC, de Marco R, de Lima MG, Foresto RD, Aguiar WF, Medina-Pestana J, Tedesco-Silva H.
    Transplantation; 2024 Jan 01; 108(1):261-275. PubMed ID: 37525373
    [Abstract] [Full Text] [Related]

  • 7. Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus.
    Ueno P, Felipe C, Ferreira A, Cristelli M, Viana L, Mansur J, Basso G, Hannun P, Aguiar W, Tedesco Silva H, Medina-Pestana J.
    Transplantation; 2017 Apr 01; 101(4):844-850. PubMed ID: 27490418
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.
    Qazi Y, Shaffer D, Kaplan B, Kim DY, Luan FL, Peddi VR, Shihab F, Tomlanovich S, Yilmaz S, McCague K, Patel D, Mulgaonkar S.
    Am J Transplant; 2017 May 01; 17(5):1358-1369. PubMed ID: 27775865
    [Abstract] [Full Text] [Related]

  • 9. Prospective randomized study comparing everolimus and mycophenolate sodium in de novo kidney transplant recipients from expanded criteria deceased donor.
    Ferreira AN, Felipe CR, Cristelli M, Viana L, Mansur J, de Paula M, Wagner D, de Marco R, Gerbase-DeLima M, Proença H, Aguiar W, Medina-Pestana J, Tedesco-Silva Junior H.
    Transpl Int; 2019 Nov 01; 32(11):1127-1143. PubMed ID: 31278785
    [Abstract] [Full Text] [Related]

  • 10. Clinical Outcomes of Everolimus With Reduced-Dose Tacrolimus vs Mycophenolate Mofetil With Standard-Dose Tacrolimus in De Novo ABO-Incompatible Kidney Transplant Recipients: 1-Year Follow-up.
    Kosoku A, Iwai T, Uchida J.
    Transplant Proc; 2022 Mar 01; 54(2):293-298. PubMed ID: 35031117
    [Abstract] [Full Text] [Related]

  • 11. Outcomes of Everolimus Plus Standard-Dose Tacrolimus Immunosuppression in De Novo Kidney Transplant: A Retrospective, Single-Center Study of 225 Transplants.
    Okabe Y, Noguchi H, Sato Y, Mei T, Kaku K, Ueki K, Tsuchimoto A, Nakamura M.
    Exp Clin Transplant; 2022 Mar 01; 20(4):362-369. PubMed ID: 35475420
    [Abstract] [Full Text] [Related]

  • 12. Cost-Effectiveness Analysis of Everolimus versus Mycophenolate in Kidney Transplant Recipients Receiving No Pharmacological Prophylaxis for Cytomegalovirus Infection: A Short-Term Pharmacoeconomic Evaluation (12 Months).
    Felipe C, Tedesco-Silva H, Ferreira Brigido A, Bessa A, Ruppel P, Hiramoto L, de Paula M, Cristelli M, Stopa S, Mansur J, Viana L, Fahham L, Pepe C, Medina-Pestana J.
    Value Health Reg Issues; 2017 Dec 01; 14():108-115. PubMed ID: 29254534
    [Abstract] [Full Text] [Related]

  • 13. Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Chhabra D, Skaro AI, Leventhal JR, Dalal P, Shah G, Wang E, Gallon L.
    Clin J Am Soc Nephrol; 2012 Mar 01; 7(3):504-12. PubMed ID: 22282478
    [Abstract] [Full Text] [Related]

  • 14. Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients.
    de Boer SE, Sanders JSF, Bemelman FJ, Betjes MGH, Burgerhof JGM, Hilbrands L, Kuypers D, van Munster BC, Nurmohamed SA, de Vries APJ, van Zuilen AD, Hesselink DA, Berger SP.
    BMC Nephrol; 2021 Jun 02; 22(1):208. PubMed ID: 34078323
    [Abstract] [Full Text] [Related]

  • 15. Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial.
    Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Nashan B, Thaiss F.
    Trials; 2016 Feb 17; 17():92. PubMed ID: 26888217
    [Abstract] [Full Text] [Related]

  • 16. Cardiovascular Outcomes in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Calcineurin Inhibitor or Standard Triple Therapy: 24-month Post Hoc Analysis From TRANSFORM Study.
    Sommerer C, Legendre C, Citterio F, Watarai Y, Oberbauer R, Basic-Jukic N, Han J, Gawai A, Bernhardt P, Chadban S.
    Transplantation; 2023 Jul 01; 107(7):1593-1604. PubMed ID: 36959121
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients.
    Hannun P, Felipe C, Ferreira A, Sandes-Freitas T, Cristelli M, Aguiar W, Franco M, Campos E, Gerbase de Lima M, Tedesco-Silva H, Medina-Pestana J.
    Ther Drug Monit; 2016 Jun 01; 38(3):293-9. PubMed ID: 26919549
    [Abstract] [Full Text] [Related]

  • 18. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
    Favi E, Citterio F, Spagnoletti G, Gargiulo A, Delreno F, Romagnoli J, Castagneto M.
    Transplant Proc; 2009 May 01; 41(4):1152-5. PubMed ID: 19460503
    [Abstract] [Full Text] [Related]

  • 19. Three-year outcomes from the CRADLE study in de novo pediatric kidney transplant recipients receiving everolimus with reduced tacrolimus and early steroid withdrawal.
    Tönshoff B, Tedesco-Silva H, Ettenger R, Christian M, Bjerre A, Dello Strologo L, Marks SD, Pape L, Veldandi U, Lopez P, Cousin M, Pandey P, Meier M.
    Am J Transplant; 2021 Jan 01; 21(1):123-137. PubMed ID: 32406111
    [Abstract] [Full Text] [Related]

  • 20. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E, Spagnoletti G, Salerno MP, Pedroso JA, Romagnoli J, Citterio F.
    Clin Transplant; 2013 Jan 01; 27(4):E359-67. PubMed ID: 23710603
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.